ORPHAZYME TO PRESENT AT INVESTORDAGEN 2018

Copenhagen, September 18, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at Dansk Aktionærforening’s InvestorDagen in Copenhagen, Denmark, today, September 18, 2018 at 10.20 AM CET.

For free participation, please visit www.InvestorDagen.dk and use the code VIPOrphazyme2018.

ORPHAZYME TO PRESENT AT BIOCENTURY 25TH ANNUAL NEWSMAKERS IN THE BIOTECH INDUSTRY

Copenhagen, September 6, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the BioCentury 25th Annual NewsMakers in the Biotech Industry in New York, USA on September 7, 2018 at 9.30 AM EDT.

ORPHAZYME INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FIRST HALF 2018 PRESENTATION

Copenhagen, August 22, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Interim Condensed Consolidated Financial Statements First Half 2018. The presentation will be followed by a Q&A session.

ORPHAZYME ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE III CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS

Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the first patient has received the first dose in its Phase III clinical trial of arimoclomol for Amyotrophic Lateral Sclerosis (ALS).

MAJOR SHAREHOLDER ANNOUNCEMENT

Copenhagen, July 6, 2018 – Orphazyme A/S (the “Company”), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that its indirect shareholding in the Company is 1,029,081 shares corresponding to 3.28% of the share capital in the Company and that Danske Bank A/S indirectly has control over 5.16% of the voting rights in the Company.

ORPHAZYME PRESENTS AT 2018 PARSEGHIAN SCIENTIFIC CONFERENCE FOR NIEMANN-PICK TYPE C RESEARCH

Copenhagen, June 4, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Orphazyme is presenting preclinical, clinical, and novel biomarker data on Niemann-Pick disease Type C (NPC) at the 2018 Parseghian Scientific Conference for Niemann-Pick Type C Research in Tucson, Arizona, USA on June 2-4, 2018.